Quest Diagnostics Stock Climbs on Apple Health Partnership

Quest Diagnostics stock closed at $235.50 on September 8, 2026, after a 0.69 percent daily drop from $237.14.

The partnership between Quest Diagnostics and Apple Health likely contributed to the move, as the company's trailing 12-month revenue stood at $11.56 billion.

According to MarketBeat, analysts have raised their Q3 2026 EPS estimate for Quest Diagnostics to $2.83 from $2.82, while maintaining a Moderate Buy consensus rating and an average price target of $236.31.

UBS has also maintained its Neutral rating but increased its price target to $245 from $232, which sits above the last close of $235.50.